Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Sciences Année : 2021

Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases

Résumé

Autoimmune disease development depends on multiple factors, including genetic and environmental. Abnormalities such as sialylation levels and/or quality have been recently highlighted. The adjunction of sialic acid at the terminal end of glycoproteins and glycolipids is essential for distinguishing between self and non-self-antigens and the control of pro- or anti-inflammatory immune reactions. In autoimmunity, hyposialylation is responsible for chronic inflammation, the anarchic activation of the immune system and organ lesions. A detailed characterization of this mechanism is a key element for improving the understanding of these diseases and the development of innovative therapies. This review focuses on the impact of sialylation in autoimmunity in order to determine future treatments based on the regulation of hyposialylation.
Fichier principal
Vignette du fichier
ijms-22-03402.pdf (1.22 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03205737 , version 1 (11-03-2024)

Identifiants

Citer

Anne Bordron, Marie Morel, Cristina Bagacean, Maryvonne Dueymes, Pierre Pochard, et al.. Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases. International Journal of Molecular Sciences, 2021, 22 (7), pp.3402. ⟨10.3390/ijms22073402⟩. ⟨hal-03205737⟩
72 Consultations
5 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More